Cardiovascular complications are among the leading causes of morbidity and mortality in diabetes mellitus (DM). Despite the anti-hyperglycemic effects of various anti-diabetic therapeutic agents like insulin, some of these drugs are implicated in precipitating cardiovascular dysfunction. There is therefore an imperative need to seek alternative drugs that may ameliorate these complications. Accordingly, the aim of the study was to investigate the effects of a dioxidovanadium (V) complex, cis-[VO₂(obz)py]) on selected cardiovascular function markers in STZ-induced diabetic rats. The vanadium complex (40 mg kg) was administered orally twice every 3rd day 5 weeks, non-diabetic and diabetic control groups received distilled water whereas the insulin group received subcutaneous insulin injections twice daily for 5 weeks. Blood glucose concentrations, mean arterial pressure (MAP), heart rate, triglycerides (TG) and total cholesterol concentrations were monitored weekly for 5 weeks. Rats were then euthanised and blood and hearts were collected for biochemical analysis. There was a significant decrease in blood glucose, triglycerides, cholesterol concentrations as well as blood pressure of vanadium treated rats compared to the untreated diabetic animals. Vanadium treatment also attenuated cardiac oxidative stress and decreased the expression of transforming growth factor β1 (TGFβ1) and Smad7. Lastly, the administration of the vanadium complex significantly decreased C reactive protein (CRP) and cardiotropin 1(CT-1) concentrations in the plasma and heart tissues. The administration of the dioxidovanadium(V) complex to diabetic rats culminated into cardio-protective effects. Taken together, these observations suggest that this metal complex exhibit a significant potential as an alternative therapeutic drug for DM management.

心血管并发症是糖尿病 (DM) 发病率和死亡率的主要原因之一。尽管各种抗糖尿病治疗剂如胰岛素具有抗高血糖作用，但其中一些药物与诱发心血管功能障碍有关。因此，迫切需要寻找可以改善这些并发症的替代药物。因此，该研究的目的是研究二氧化钒 (V) 配合物顺式-[VO ₂(obz)py]) 在 STZ 诱导的糖尿病大鼠中选定的心血管功能标志物。钒复合物（40mg/kg）每三天口服两次，持续 5 周，非糖尿病和糖尿病对照组接受蒸馏水，而胰岛素组接受皮下注射胰岛素，每天两次，持续 5 周。每周监测血糖浓度、平均动脉压 (MAP)、心率、甘油三酯 (TG) 和总胆固醇浓度，持续 5 周。然后对大鼠实施安乐死并收集血液和心脏用于生化分析。与未治疗的糖尿病动物相比，钒治疗的大鼠的血糖、甘油三酯、胆固醇浓度和血压显着降低。钒处理还减弱了心脏氧化应激并降低了转化生长因子 β1 (TGFβ1) 和 Smad7 的表达。最后，钒复合物的给药显着降低了血浆和心脏组织中的 C 反应蛋白 (CRP) 和心脏激素 1(CT-1) 浓度。二氧化钒（V）复合物对糖尿病大鼠的给药最终产生了心脏保护作用。综上所述，这些观察结果表明，这种金属络合物作为 DM 管理的替代治疗药物表现出巨大的潜力。二氧化钒（V）复合物对糖尿病大鼠的给药最终产生了心脏保护作用。综上所述，这些观察结果表明，这种金属络合物作为 DM 管理的替代治疗药物表现出巨大的潜力。二氧化钒（V）复合物对糖尿病大鼠的给药最终产生了心脏保护作用。综上所述，这些观察结果表明，这种金属络合物作为 DM 管理的替代治疗药物表现出巨大的潜力。